Logo

Merck Entered into a Definitive Agreement to Acquire Imago BioSciences for ~$1.35B

Share this
Merck Entered into a Definitive Agreement to Acquire Imago BioSciences for ~$1.35B

Merck Entered into a Definitive Agreement to Acquire Imago BioSciences for ~$1.35B

Shots:

  • Merck to acquire Imago for $36.00/share in cash for a total equity value of $1.35B. The transaction is expected to close in Q1’23
  • The acquisition will use Merck’s industry-leading clinical development expertise to maximize the therapeutic potential of bomedemstat for patients with myeloproliferative neoplasms. The acquisition also strengthens Merck’s growing hematology portfolio
  • Additionally, Imago’s bomedemstat (IMG-7289) is an orally available LSD1 inhibitor & is currently being studied in multiple P-II clinical trials for essential thrombocythemia (ET), MF, and PV along with other indications

Ref: Merck | Image: Merck

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions